Table 4: Comparison of changes in the clinical and biochemical parameters during the study period between the intervention and control groups across glibenclamide, metformin, and metformin + glibenclamide treatment subgroups.

GlibenclamideMetforminGlibenclamide + metformin
Control groupIntervention groupP valueControl groupIntervention groupP valueControl groupIntervention groupP value

Systolic blood pressure0.01
(−5.00, 1.25)
−10.00
(−16.25, −3.75)
0.016*0.01
(−1.25, 10.00)
−10.00
(−10.00, 0.01)
0.043*0.01
(0.01, 5.00)
−10.00
(−12.50, −2.50)
0.003*
Fasting glucose13.0
(4.50, 31.50)
−25.00
(−84.50, −5.75)
<0.0001*2.00
(−3.50, 12.00)
−25.00
(−32.00, −10.00)
0.005*7.00
(1.00, 22.00)
−32.00
(−47.50, −22.50)
<0.0001*
Insulin0.06
(−3.85, 5.39)
−4.42
(−7.85, −2.31)
0.042*0.73
(0.06, 1.05)
−1.32
(−3.39, −0.04)
0.0880.37
(0.32, 0.95)
−7.71
(−9.31, −1.96)
0.002*
HbA1c−0.15
(−1.04, 0.200)
−1.55
(−2.22, −0.97)
0.031*−0.15
(−0.70, 0.22)
−0.60
(−2.00, −0.02)
0.1330.05
(−0.10, 0.50)
−1.10
(−2.05, −0.90)
<0.0001*
HOMA-IR0.17
(−1.53, 3.69)
−2.12
(−5.07, −1.16)
0.022*0.27
(0.15, 0.65)
−0.86
(−1.25, −0.31)
0.043*0.24
(−0.26, 0.56)
−2.86
(−5.22, −1.12)
<0.0001*
HDL-cholesterol−1.65
(−5.77, 1.40)
6.25
(2.82, 11.26)
0.003*0.10
(−4.07, 2.95)
4.60
(1.40, 12.05)
0.043*−2.80
(−4.70, 0.60)
6.10
(0.35, 11.20)
<0.0001*
LDL-cholesterol8.0
(5.50, 18.0)
−17.50
(−35.75, −10.50)
0.005*4.50
(−1.25, 20.75)
−7.0
(−70.00, 2.00)
0.007*1.00
(−2.00, 4.00)
−9.00
(−32.00, 1.50)
0.030*

Data is presented as medians (Interquartile ranges). versus control group. HOMA-IR: homeostasis model of assessment for insulin resistance; HbA1c: Hemoglobin A1c; HDL: high density lipoprotein; LDL: low density lipoprotein.